Ignite Creation Date:
2024-05-06 @ 1:43 AM
Last Modification Date:
2024-10-26 @ 11:09 AM
Study NCT ID:
NCT01886378
Status:
COMPLETED
Last Update Posted:
2021-02-11
First Post:
2013-06-18
Brief Title:
A Study of UX007 Triheptanoin in Participants With Long-Chain Fatty Acid Oxidation Disorders LC-FAOD
Sponsor:
Ultragenyx Pharmaceutical Inc
Organization:
Ultragenyx Pharmaceutical Inc
Study Overview
Official Title:
An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders LC-FAOD
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03773770
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
None
Brief Summary:
The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-004830-14 | EUDRACT_NUMBER | None | None |